X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (612) 612
index medicus (445) 445
secondary hyperparathyroidism (407) 407
calcimimetics (334) 334
male (314) 314
urology & nephrology (307) 307
cinacalcet (292) 292
female (270) 270
hyperparathyroidism (262) 262
cinacalcet hydrochloride (261) 261
parathyroid hormone (261) 261
hyperparathyroidism, secondary - drug therapy (242) 242
calcium-sensing receptor (221) 221
middle aged (216) 216
calcimimetic agents - therapeutic use (213) 213
naphthalenes - therapeutic use (201) 201
parathyroid hormone - blood (195) 195
calcium (187) 187
animals (177) 177
calcimimetic (172) 172
calcium - blood (159) 159
hemodialysis-patients (152) 152
adult (145) 145
aged (145) 145
hyperparathyroidism, secondary - etiology (144) 144
vitamin d (140) 140
hemodialysis (132) 132
treatment outcome (127) 127
chronic kidney-disease (124) 124
parathyroidectomy (124) 124
parathyroid-hormone (121) 121
renal dialysis (117) 117
kidney failure, chronic - complications (116) 116
calcium - metabolism (108) 108
chronic kidney disease (108) 108
pharmacology & pharmacy (107) 107
dialysis (98) 98
receptors, calcium-sensing - metabolism (96) 96
hyperparathyroidism, secondary - blood (91) 91
nephrology (89) 89
stage renal-disease (86) 86
endocrinology & metabolism (85) 85
calcimimetic agent (83) 83
rats (83) 83
kidney failure, chronic - therapy (82) 82
vascular calcification (80) 80
hypercalcemia (79) 79
mineral metabolism (79) 79
transplantation (79) 79
cinacalcet hydrochloride - therapeutic use (77) 77
medicine & public health (76) 76
dialysis patients (75) 75
phosphorus (75) 75
vitamin-d (69) 69
extracellular ca2+-sensing receptor (65) 65
phosphorus - blood (65) 65
vitamin d - therapeutic use (65) 65
disease (63) 63
hyperparathyroidism - drug therapy (62) 62
cinacalcet hcl (61) 61
mortality (61) 61
naphthalenes - pharmacology (61) 61
primary hyperparathyroidism (60) 60
cardiovascular-disease (57) 57
surgery (57) 57
hcl (56) 56
naphthalenes - adverse effects (56) 56
time factors (56) 56
chronic-renal-failure (55) 55
familial hypocalciuric hypercalcemia (55) 55
renal insufficiency, chronic - complications (55) 55
expression (53) 53
risk factors (53) 53
kidney diseases (52) 52
calcimimetic agents - administration & dosage (51) 51
calcimimetic agents - adverse effects (51) 51
parathyroid-hormone levels (51) 51
receptors, calcium-sensing - genetics (51) 51
ca2+-sensing receptor (50) 50
calcimimetic amg-073 (50) 50
chronic kidney failure (50) 50
naphthalenes - administration & dosage (50) 50
propylamines (50) 50
renal dialysis - adverse effects (50) 50
care and treatment (49) 49
phosphate (49) 49
prospective studies (49) 49
kidney transplantation (48) 48
phenethylamines (48) 48
calcimimetic agents - pharmacology (46) 46
calcimimetic compound (46) 46
patients receiving hemodialysis (46) 46
physiological aspects (46) 46
analysis (45) 45
receptors, calcium-sensing - agonists (45) 45
biomarkers - blood (44) 44
calcification (44) 44
hypercalcemia - drug therapy (43) 43
medicine, general & internal (43) 43
pth (43) 43
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (847) 847
French (27) 27
German (21) 21
Spanish (20) 20
Japanese (12) 12
Polish (7) 7
Czech (6) 6
Italian (5) 5
Swedish (2) 2
Chinese (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drug Metabolism and Disposition, ISSN 0090-9556, 08/2016, Volume 44, Issue 8, pp. 1319 - 1331
Journal Article
Journal Article
JAMA, ISSN 0098-7484, 01/2017, Volume 317, Issue 2, pp. 156 - 164
IMPORTANCE: Secondary hyperparathyroidism contributes to extraskeletal calcification and is associated with all-cause and cardiovascular mortality. Control is... 
MEDICINE, GENERAL & INTERNAL | CALCIUM-SENSING RECEPTOR | PEPTIDE AGONIST | EVOLVE TRIAL | CARDIOVASCULAR-DISEASE | MINERAL METABOLISM | BONE | CHRONIC KIDNEY-DISEASE | AMG 416 VELCALCETIDE | FGF23 | DIALYSIS | Calcimimetic Agents - administration & dosage | Nausea - chemically induced | Cinacalcet Hydrochloride - pharmacology | Humans | Middle Aged | Calcium - administration & dosage | Male | Cinacalcet Hydrochloride - administration & dosage | Parathyroid Hormone - blood | Peptides - administration & dosage | Calcium - blood | Time Factors | Calcimimetic Agents - pharmacology | Cinacalcet Hydrochloride - adverse effects | Female | Double-Blind Method | Hyperparathyroidism, Secondary - drug therapy | Administration, Oral | Biomarkers - blood | Calcimimetic Agents - adverse effects | Peptides - pharmacology | Kidney Failure, Chronic - therapy | Hyperparathyroidism, Secondary - blood | Vomiting - chemically induced | Fibroblast Growth Factors - blood | Kidney Failure, Chronic - complications | Infusions, Intravenous | Hyperparathyroidism, Secondary - etiology | Peptides - adverse effects | Renal Dialysis | Complications and side effects | Usage | Care and treatment | Parathyroid hormone | Hemodialysis | Dosage and administration | Research | Cinacalcet | Hyperparathyroidism | Patient safety | Endocrine system | Hyperthyroidism | Clinical outcomes
Journal Article
JAMA, ISSN 0098-7484, 01/2017, Volume 317, Issue 2, pp. 146 - 155
Journal Article
Journal Article
Annual Review of Medicine, ISSN 0066-4219, 01/2001, Volume 52, pp. 203 - 220
The discovery, characterization, and cloning of the calcium-sensing receptor (CaR) in 1993 was soon followed by the creation of a new type of drug, the... 
calcimimetic
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 12, Issue 12, p. CD006254
Journal Article
Pediatric Nephrology, ISSN 0931-041X, 10/2012, Volume 27, Issue 10, pp. 1953 - 1959
Journal Article
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 2015, Volume 10, Issue 1, pp. 98 - 109
Background and objectivesElevated parathyroid hormone levels may be associated with adverse clinical outcomes in patients on dialysis. After the introduction... 
ESRD | dialysis | parathyroid hormone | PERITONEAL-DIALYSIS | hyperparathyroidism | DIALYSIS PATIENTS | CLINICAL-PRACTICE GUIDELINE | CARDIOVASCULAR-DISEASE | MAINTENANCE HEMODIALYSIS | UROLOGY & NEPHROLOGY | PARATHYROID-HORMONE | MINERAL METABOLISM | RENAL REPLACEMENT | CHRONIC KIDNEY-DISEASE | CKD | PRACTICE PATTERNS | Hyperparathyroidism, Secondary - therapy | Up-Regulation | Naphthalenes - adverse effects | Prospective Studies | Parathyroidectomy - adverse effects | Humans | Middle Aged | Male | Parathyroid Hormone - blood | Renal Insufficiency, Chronic - complications | Renal Insufficiency, Chronic - therapy | Renal Dialysis - mortality | Time Factors | Renal Insufficiency, Chronic - mortality | Adult | Female | Parathyroidectomy - mortality | Renal Insufficiency, Chronic - diagnosis | Dietary Supplements - adverse effects | Parathyroidectomy - trends | Risk Assessment | Risk Factors | Treatment Outcome | Biomarkers - blood | Calcimimetic Agents - adverse effects | Calcimimetic Agents - therapeutic use | Renal Insufficiency, Chronic - blood | Vitamin D - adverse effects | Hyperparathyroidism, Secondary - blood | Cinacalcet Hydrochloride | Hyperparathyroidism, Secondary - diagnosis | Hyperparathyroidism, Secondary - mortality | Renal Dialysis - adverse effects | Aged | Vitamin D - therapeutic use | Hyperparathyroidism, Secondary - etiology | Naphthalenes - therapeutic use | Original
Journal Article
16.